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Abstract
Introduction IL-1β is a proinflammatory cytokine driving joint
inflammation as well as systemic signs of inflammation, such as
fever and acute phase protein production.
Methods ACZ885, a fully human monoclonal antibody that
neutralizes the bioactivity of human IL-1β, was generated to
study the potent and long-lasting neutralization of IL-1β in
mechanistic animal models as well as in a proof-of-concept
study in patients with rheumatoid arthritis (RA).
Results The mouse IL-1 receptor cross-reacts with human IL-
1β, and it was demonstrated that ACZ885 can completely
suppress IL-1β-mediated joint inflammation and cartilage
destruction in mice. This observation prompted us to study the
safety, tolerability and pharmacodynamic activity of ACZ885 in
RA patients in a small proof-of-concept study – the first to be
conducted in humans. Patients with active RA despite treatment
with stable doses of methotrexate were enrolled in this dose
escalation study. The first 32 patients were split into four
cohorts of eight patients each (six were randomly assigned to
active treatment and two to placebo). ACZ885 doses were 0.3,
1, 3 and 10 mg/kg, administered intravenously on days 1 and
15. To explore efficacy within 6 weeks of treatment, an
additional 21 patients were randomly assigned to the 10 mg/kg
cohort, resulting in a total of 20 patients dosed with 10 mg/kg
and 15 patients treated with placebo. There was clinical
improvement (American College of Rheumatology 20%
improvement criteria) at week 6 in the 10 mg/kg treatment
group; however, this did not reach statistical significance (P =
0.085). A statistically significant reduction in disease activity
score was observed after 4 weeks in the 10 mg/kg group. Onset
of action was rapid, because most responders exhibited
improvement in their symptoms within the first 3 weeks. C-
reactive protein levels decreased in patients treated with
ACZ885 within 1 week. ACZ885 was well tolerated. Three
patients receiving ACZ885 developed infectious episodes that
required treatment. No anti-ACZ885 antibodies were detected
during the study.
Conclusion ACZ885 administration to methotrexate-refractory
patients resulted in clinical improvement in a subset of patients.
Additional studies to characterize efficacy in RA and to
determine the optimal dose regimen appear warranted.
Trial Registration ClinicalTrials.gov identifier NCT00619905.
ACR = American College of Rheumatology; CRP = C-reactive protein; DAS28 = Disease Activity Score using 28 joint counts; ED50 = dose effective 
to achieve a mean of 50% improvement; EULAR = European League Against Rheumatism; h = human; IL = interleukin; IL-1Ra = IL-1 receptor antag-
onist; RA = rheumatoid arthritis; TNF = tumour necrosis factor.Arthritis Research & Therapy    Vol 10 No 3    Alten et al.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease of
the joints that is associated with destruction of cartilage and
bone. In addition to its local destructive nature, it also can have
a pronounced systemic inflammatory component, presenting
as fever, headache and fatigue, and may even affect other
organs such as the skin, liver, spleen and lymph nodes. The
contribution made by proinflammatory cytokines such as
tumour necrosis factor (TNF)-α and IL-1 has been validated in
preclinical animal models and in humans [1,2].
Current therapy targeting IL-1 in RA is based on a recombinant
form of the IL-1 receptor antagonist (IL-1Ra; anakinra), which
binds to the IL-1 receptor without eliciting a signal and there-
fore competes with the binding of the two natural ligands,
namely IL-1α and IL-1β. As compared with TNF-α inhibitors, it
appears that treatment with the recombinant IL-1Ra is less effi-
cacious in RA [3]. However, it is unclear whether this is due to
biological superiority of TNF-α over IL-1 in RA pathogenesis
[4] or whether the approach to block the IL-1 receptor with
anakinra is only partly effective in neutralizing IL-1 activity in
vivo because of short half-life or inability to achieve sufficient
exposure at the target site with the current dosing regimen [5].
The main elicitor of inflammatory responses in preclinical ani-
mal models appears to be IL-1β and not IL-1α. In murine col-
lagen-induced arthritis [6] and antigen-induced arthritis [7,8],
inflammation and cartilage degradation were inhibited by
blocking IL-1β but not IL-1α. In RA patients, IL-1β is over-
expressed in inflamed synovial tissue, in particular in the lining
layer and in sublining cells [9], and it is elevated in draining
lymph from affected joints [10]. Furthermore, IL-1β is localized
to the synovial pannus in close proximity to bone and cartilage
[11], and cartilage from arthritis patients exhibits upregulation
of IL-1β mRNA as compared with normal cartilage. Increased
levels of IL-1β in synovial fluid [12] have been described and
were found to correlate with histological features of RA
[13,14]. Treatment with anakinra demonstrated improvement
in histological characteristics of RA joint pathology [15], and
evidence was provided that it delays the progression of radio-
graphic joint damage [16]. Thus, there is reason to believe that
IL-1β is a crucial cytokine that drives inflammation and joint
destruction in RA.
We report here results of preclinical studies and a proof-of-
concept study in patients with RA, using a fully monoclonal
antibody (ACZ885) directed against human IL-1β. ACZ885 is
expected to have the half-life of a typical IgG1 antibody, thus
ensuring full neutralization of IL-1β over a longer period of time
as compared with recombinant IL-1Ra; the therefore study
explored pharmacodynamic effects in RA patients (secondary
to an evaluation of safety).
Materials and methods
In vivo activity of ACZ885 in a human IL-1β-dependent 
mouse model of joint inflammation
Cells of the murine fibroblast line 3T3NIH were transfected
with retroviral vector DFG-hIL-1β-neo, which contains the
cDNAs for human (h)IL-1β and neomycin phosphotransferase
(neoR), as described previously [17]. The 3T3NIH fibroblast
cell line was derived from a DBA background. One clone
derived from the transduction, namely IB2 (3T3-hIL-1β), was
selected, which produced high levels of hIL-1β (220 ng hIL-
1β/24 hours per 106 cells) in vitro. hIL-1β-induced arthritis
was induced by intra-articular injection of 104 IB2 cells into the
right knee joints of DBA-1 mice. Mice were injected with
ACZ885 or isotype control antibody CHI621, which is specific
for human CD25 and does not cross-react with mouse cells or
tissue. All mice were housed in filter top cages, and water and
food were supplied ad libitum. The mice were studied at age
10 to 14 weeks. All animal experiments were approved by the
Nijmegen University Animal Ethics Committee.
Administration of antibodies was intraperitoneal 2 hours
before intra-articular injection of the IB2 clone. Joint inflamma-
tion was quantified using the 99mTc uptake method [18]. By
external gamma counting, this method measures the accumu-
lation of a small radioisotope at the site of inflammation caused
by locally increased blood flow and tissue swelling. The sever-
ity of inflammation is expressed as the ratio of 99mTc uptake in
the right (inflamed) to that in the left (control) knee joint.
Proteoglycan synthesis was assayed as follows. Patellae with
minimal surrounding tissue were placed in RPMI 1640
medium with glutamax, gentamycin (50 μg/ml) and 35S-sul-
phate (0.74 MBq/ml). After 3 hours of incubation at 37°C in a
carbon dioxide incubator, patellae were washed in saline three
times, fixed in 4% formaldehyde and subsequently decalcified
in 5% formic acid for 4 hours. Patellae were punched out of
the adjacent tissue, dissolved in 0.5 ml Luma Solve at 65°C
(Omnilabo, Breda, The Netherlands), and after addition of 10
ml Lipoluma (Omnilabo) the 35S content was measured using
liquid scintilation counting. For histological analysis, whole
knee joints were removed and fixed in 4% formaldehyde for 7
days before decalcification in 5% formic acid and processing
for paraffin embedding. Tissue sections (7 μm) were stained
with haematoxylin/eosin or safranin O/fast green. Histopatho-
logical changes in the knee joints were scored in the patella/
femur region on five semi-serial sections, spaced 140 μm
apart. Scoring was performed on decoded slides by two sep-
arate observers, using the following parameters. In the haema-
toxylin/eosin stained slides the amount of cells infiltrating the
synovial lining and the joint cavity was scored from 0 to 3. Pro-
teoglycan depletion was scored in the safranin O stained
slides on a scale from 0 to 3 (ranging from stained cartilage to
fully destained cartilage). Cartilage damage was scored from
0 to 3 (ranging from unaffected cartilage to maximum chondro-
cyte death and cartilage destruction).Available online http://arthritis-research.com/content/10/3/R67
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Design of clinical study
This was a randomized, double-blind, placebo-controlled,
dose escalation study conducted to explore the safety, tolera-
bility, pharmacokinetics and pharmacodynamics of ACZ885 in
patients with active RA, despite ongoing treatment with a sta-
ble dose of methotrexate (MTX) of 15 mg/week or more for at
least 3 months (CACZ885A2101). It is the first of its kind to
be conducted in humans. Patients receiving stable doses of
10 mg/week methotrexate could be included if the patients
could not tolerate higher doses.
Included patients were required to have a diagnosis of RA
(American College of Rheumatology [ACR] 1987 revised
classification for criteria for RA) with a disease duration of at
least 6 months before randomization; active disease at screen-
ing; baseline evaluation (same evaluator) indicating more than
six tender and six swollen joints out of 28 examined (including
any effused joint); and either Westergren erythrocyte sedimen-
tation rate of 28 mm/hour or greater, or C-reactive protein
(CRP) of at least 6 mg/l. The inclusion criteria also required
patients were have failed at least one disease-modifying
antirheumatic drug in the past, but not deemed 'refractory to
all therapies'. Their current treatment regimen included at least
15 mg methotrexate/week and with the current dose stable for
approximately 3 months. Patients were required to have an
otherwise stable RA therapeutic regimen, consisting of either
a stable dose of nonsteroidal anti-inflammatory drugs and/or a
stable dose of oral corticosteroids (prednisone or equivalent <
10 mg/day) for at least 4 weeks before randomization.
This multicentre study was conducted in accordance with
GCP (Good Clinical Practice) guidelines and the Helsinki
Declaration in three countries in Europe. The study protocol
and patient informed consent form was approved by local eth-
ics committees and health authorities. The primary objective
was to evaluate the safety and tolerability of ACZ885 adminis-
tered as an intravenous infusion. Secondary objectives
included assessment of the preliminary biologic activity/phar-
macodynamics of ACZ885 using ACR criteria for clinical
response and Disease Activity Score using 28 joint counts
(DAS28), evaluation of the pharmacokinetics of ACZ885 and
examination of the potential immunogenicity of ACZ885.
The initial dose escalation phase of the study consisted of four
cohorts (Figure 1). In each cohort six patients were randomly
assigned to receive ACZ885 and two patients were randomly
assigned to receive placebo. In the first cohort, patients ran-
domly assigned to ACZ885 received 0.3 mg/kg intravenously
on days 1 and 15. Safety data from a minimum of six out of
eight patients in this cohort up to day 20 were reviewed prior
to proceeding with the study and starting the next higher dose.
Patients randomly assigned to ACZ885 in the second cohort
received 1 mg/kg, in the third cohort 3 mg/kg, and finally in the
fourth cohort 10 mg/kg. Safety data from the 10 mg/kg cohort
were found to raise no concern that might prevent proceeding
with the study, so this cohort was extended to increase the
sample size, such that in total 20 patients received 10 mg/kg
intravenous on days 1 and 15, and a total of 15 patients
received placebo. Thus, a total of 53 patients with RA were
enrolled.
Figure 1
Study design Study design. Sequential dose-escalation, randomized, double-blind, placebo controlled study design with an extension at the highest dose level. 
ACZ885 was administered intravenously on days 1 and 15 (arrows). Safety data generated up to day 20 in each cohort were reviewed before esca-
lating to the next higher dose level. Independent observer efficacy assessments were made at day 1, before dosing, and day 43, in addition to weekly 
investigator assessments up to Day 43. The end of study was on day 113. After safety review of the first six patients at 10 mg/kg, an extension 
cohort was started, which included 14 patients on ACZ885 and seven patients on placebo (pbo).Arthritis Research & Therapy    Vol 10 No 3    Alten et al.
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ACR response criteria were evaluated at baseline and on days
8, 15, 22, 29 and 43 by the investigator, and at baseline and
day 43 by a blinded observer at each site who was not other-
wise involved in the study. Overall, there was no evidence of a
systematic bias between the blinded observer and the investi-
gator assessments. Patients were further followed for safety
and pharmacokinetic assessments, and a formal end of study
was reached at day 113. Investigators were free to change
treatment after day 43 as they deemed necessary.
Statistical analyses
Statistical analyses were performed on the ACR 20%, 50%
and 70% response criteria (ACR20, ACR50 and ACR70)
rates. Separate statistical analyses were performed on the
response rate at day 43 (assessed by a blinded observer) and
the response rate up to and including day 43. Fisher's exact
test was used to compare treatment groups. From these anal-
yses, one sided P values are presented. The primary compari-
son was the comparison between the 10 mg/kg treatment
group and placebo at day 43. For the DAS28 measurements,
a repeated measures mixed effect analysis was performed.
Baseline DAS28 was included in the model as a covariate. An
unstructured correlation structure was assumed to adjust for
correlation within patients. From this model the adjusted mean
difference for each treatment group versus placebo at each
time point was calculated, along within its 95% confidence
interval. No multiplicity adjustments were made to the confi-
dence intervals. A similar analysis was performed on the CRP
measurements; however, because of the skewness of the
CRP measurements, the analysis was performed on the loge
scale and results were back-transformed onto the original
scale.
The inclusion of six patients per dose group in each escalation
step provided an 80% probability that at least one patient
would report an adverse event that has an underlying inci-
dence rate of 24%. With 20 patients receiving the highest
ACZ885 dose (six patients in the last escalation step plus 14
patients in the expansion phase) and 15 patients receiving pla-
cebo (two patients in each of the four escalation steps plus
seven patients in the expansion phase), there was at least
80% power to detect a statistically significant difference in
ACR20 response rate comparing ACZ885 with placebo,
assuming an underlying odds ratio of 6, a 5% significance
level and a one-side test approach. Given an anticipated pla-
cebo ACR20 response rate of 20%, an odds ratio of 6 would
translate into an ACR20 respo n s e  r a t e  o f  6 0 %  f o r  t h e
ACZ885 treatment group.
Results
ACZ885 is a human antibody that binds to human IL-1β 
with high affinity and neutralizes human IL-1β in vitro 
and in vivo
ACZ885 was derived by subjecting genetically engineered
mice carrying part of the human immunoglobulin repertoire to
immunization with human IL-1β. The antibody was initially iden-
tified from a hybridoma derived from these mice because of its
ability to bind human IL-1β with high affinity (about 40 pmol/l).
No cross-reactivity toward rodent IL-1β or human IL-1α was
observed for ACZ885. The antibody was found to neutralize
the bioactivity of human IL-1β on primary human fibroblasts in
vitro with an 50% inhibitory concentration of 44.6 pmol/l (7.1
± 0.56 ng/ml; n = 6).
IL-1β requires highly potent antagonists in large excess to neu-
tralize its biological activity in vivo. Anti-cytokine antibodies
with low neutralizing capacity can potentially lead to enhanced
bioactivity of the targeted cytokine by prolonging its half-life in
vivo [19]. In light of this potential complication, we considered
demonstration that ACZ885 is devoid of any biologically rele-
vant carrier effect in an in vivo model to be an important pre-
requisite for conducting clinical trials. Therefore, we created
an artificial mouse model of joint inflammation that relies upon
continuous secretion of human IL-1β by transfected mouse
NIH3T3 cells injected into one knee joint. Whereas IL-1β
driven inflammation becomes apparent after 24 hours and
leads to total destruction of the joint within 7 to 10 days, con-
trolateral joints or joints receiving control 3T3 cells do not
exhibit signs of inflammation. Application of ACZ885 intraperi-
toneally 2 hours before injecting the IL-1β producing cells
completely suppressed joint swelling, with a 50% effective
dose (the dose effective to reduce inflammation by a mean of
50%; ED50) of 0.06 mg/kg (Figure 2a). Also, treatment with
ACZ885 restored the ability of cartilage explants to synthesize
proteoglycan, which is otherwise suppressed in IL-1β exposed
cartilage (Figure 2b). In addition, histopathology taken at day
3 after injection of 3T3-hIL-1β cells revealed that administra-
tion of AC885 protected against severe joint destruction (Fig-
ure 2c). Apart from the strong reduction of the joint
inflammation (numbers of cells in the synovial tissues), no
bone erosion was noted in the AC885 treated animals com-
pared with controls. Thus, ACZ885 has sufficient potency to
neutralize fully the biological activity of human IL-1β, even
when it is produced at high concentrations in vivo, and it does
not significantly prolong IL-1 activity.
Proof-of-concept clinical trial in patients with RA
A proof-of-concept study to explore safety and tolerability,
pharmacokinetics and pharmacodynamics was conducted in
patients with established RA with ongoing disease despite
stable treatment with MTX. (Some of the data from this study
were presented at EULAR [European League Against Rheu-
matism] in 2006 [20].) An overview of patient demographics
at baseline is given in Table 1, and the design of the study is
presented in Figure 1.
In the 10 mg/kg cohort there were six out of 19 (32%) ACR20
responders at day 43, as assessed by the blinded observer,
versus one out of 15 (7%) in the placebo group (one-sided P
= 0.085; Table 2). ACR50 and ACR70 improvements wereAvailable online http://arthritis-research.com/content/10/3/R67
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observed at the highest dose levels (3 and 10 mg/kg) in a total
of four out of 25 patients, but no such responses were
observed in the placebo group. Using the investigator assess-
ments, 10 out of 20 patients (50%) achieved an ACR20 and
four out of 20 an ACR50 or better response at any time point
up to and including day 43 (Table 2). There was a statistically
significant difference compared with placebo in terms of
ACR20 improvement when all ACZ885 cohorts (one-sided P
= 0.043) or when the 3 mg/kg and 10 mg/kg cohorts were
pooled (one-sided P = 0.035). Nine out of the 10 ACR20
responders satisfied criteria for response within 3 weeks after
the first infusion. The time to achieve an ACR50 response was
1 week in one patient, 3 weeks in a second patient, and 4
weeks in two patients. Under placebo, three out of 15 patients
exhibited an observable ACR20 response during the 6-week
period of observation. One patient had an ACR20 response
after 1 week, which disappeared thereafter. A second patient
had an ACR20 response at weeks 1 and 3 but not on any
Figure 2
Blocking of IL-1 in mouse models of arthritis Blocking of IL-1 in mouse models of arthritis. (a) Inhibition of swelling. Mice were given different doses of ACZ885 or a control anti-CD25 antibody 
(CHI621, 12 mg/kg) intraperitoneally before injection of 10,000 3T3-huIL-1β cells into the right hind knee joint. Swelling was measured 3 days after 
cell injection (as described in Materials and methods) and is expressed as the ratio between the right (treated) and left (untreated) joint. The results 
presented represent the mean ± standard error or the mean (SEM; n = 5). **P < 0.01 by analysis of variance followed by Dunnett's test for multiple 
comparisons post hoc. NS, not significant. (b) Proteoglycan (PG) synthesis by chondrocytes in explanted patellae was measured by incorporation of 
35S labelled sulphate in isolated cartilage from treated (right) and untreated (left) knee joints. The results are given as the ratio of 35S incorporation 
between right and left knee cartilage and represent the mean ± SEM (n = 5). Statistical analysis of the treated groups versus the control group 
(CHI621) was performed by analysis of variance followed by Dunnett's test for multiple comparisons post hoc. *P < 0.05; **P < 0.01. ED50, dose 
needed to achieve a mean of 50% effect. (c) Histology was analyzed at day 3 after local injection of 3T3-hIL-1β producing cells. Section of a mouse 
knee joint treated with isotype control antibody or AC885 are shown. Hematoxylin and eosin staining, original magnification (200×). Quantitative 
evaluation of the slides was done as described in Materials and methods and is presented in the graph. n = 5 joints per group; all comparisons 
between active and control were significant (P < 0.05, Mann-Whitney U-test).Arthritis Research & Therapy    Vol 10 No 3    Alten et al.
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other occasion. The third patient had an ACR20 response
after 3 weeks which continued after day 43.
Figure 3a shows the mean reduction in DAS28 in the cohort
treated with 10 mg/kg as compared with placebo. The P val-
ues for the treatment comparisons at days 29 and 43 were
0.024 and 0.081, respectively. Using the EULAR response cri-
teria, a subset of five out of 20 patients treated with 10 mg/kg
ACZ885 achieved a good response, and 10 out of 20
achieved a moderate response at any time point up to and
including day 43 under 10 mg/kg. Four out of five patients who
were classified as good responders achieved the necessary
DAS28 reduction within the first 3 weeks of treatment, indicat-
ing a rapid onset of action.
The fact that about 50% of all patients exhibited clinical benefit
within the first 6 weeks of treatment prompted us to analyze
CRP levels under therapy as a potential marker of response
versus nonresponse. As shown in Figure 3b, there was a sub-
stantial mean reduction in and normalization of CRP within a
few days after commencing treatment with 10 mg/kg
ACZ885. Similarly, CRP was also reduced upon treatment in
the other active treatment cohorts (data not shown). As dem-
onstrated in Table 3 for the 10 mg/kg cohort, a reduction in
CRP at day 43 was required to achieve a ACR20 or higher
response; however, eight subjects had a more than 50%
reduction in CRP but had no detectable clinical response
based on ACR20 criteria. Thus, CRP levels declined under
ACZ885 treatment in the majority of patients (14/18 patients
Table 1
Baseline demographics of participating patients
Characteristic ACZ885
0.3 mg/kg (n = 6) 1.0 mg/kg (n = 6) 3.0 mg/kg (n = 6) mg/kg (n = 20) Placebo (n = 15)
Age (years; mean ± SD) 61 ± 7 53 ± 14 57 ± 7 50 ± 11 55 ± 10
hsCRP (mg/l; median [range]) 17.8 (1.6–95.3) 43.8 (5.8–89.3) 3.0 (2.0–43.4) 11.1 (1.5–28.4) 6.4 (0.2–66.2)
DAS28 (mean ± SD) 6.5 ± 0.8 6.6 ± 1.2 6.7 ± 1.5 6.2 ± 0.7 6.7 ± 0.6
Number of tender joints (mean ± SD) 17 ± 9.2 15 ± 6.2 22 ± 8.5 17 ± 7.3 20 ± 6.3
Number of swollen joints (mean ± SD) 13 ± 6.3 12 ± 4.3 12 ± 7.4 11 ± 4.8 12 ± 5.2
Methotrexate dose (n/mg median [range])a
Oral 6/17.5 (15–25) 5/15 (10–15) 4/15 (15–15) 13/15 (10–22.5) 5/15 (10–20)
Parenteral 0 1/10 (10–10) 2/22.5 (20–25) 7/15 (10–22.5) 10/15 (10–25)
aNumbers of patients receiving 15 mg/week were 2, 4, 4, 10 and 6 in the 0.3, 1, 3, 10 mg/kg and placebo cohorts, respectively. SD, standard 
deviation.
Table 2
Clinical improvement as assessed by ACR criteria
Assessor (time point) Response ACZ885 Placebo 
(n = 15)
P value 
(10 mg/kg versus 
placebo)
0.3 mg/kg 
(n = 6)
1.0 mg/kg 
(n = 6)
3.0 mg/kg 
(n = 6)
10 mg/kg 
(n = 19/20a)
Blinded observer 
(day 43)
ACR20 1 (17%) 0 (0%) 4 (67%) 6 (32%) 1 (7%) 0.085
ACR50 0 (0%) 0 (0%) 1 (17%) 3 (16%) 0 (0%) 0.162
ACR70 0 (0%) 0 (0%) 0 (0%) 2 (11%) 0 (0%) 0.305
Investigator 
(any time within 6 weeks of treatment start)
ACR20 3 (50%) 2 (33%) 4 (67%) 10 (50%) 3 (20%) 0.070
ACR50 0 (0%) 0 (0%) 2 (33%) 4 (20%) 0 (0%) 0.093
ACR70 0 (0%) 0 (0%) 0 (0%) 3 (15%) 0 (0%) 0.174
Shown are the number and percentage of patients achieving 20%, 50%, or 70% improvement in terms of American College of Rheumatology 
(ACR) criteria (ACR20, ACR50 and ACR70, respectively) at day 43 as assessed by a blinded observer and at any time point within 6 weeks of 
treatment start as assessed by the investigator. aNote that for one patient in the 10 mg/kg treatment group, the ACR criteria assessment by a 
blinded observer was not conducted at day 43.Available online http://arthritis-research.com/content/10/3/R67
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amenable for analysis), but only six of the CRP responders
achieved an ACR20 response at day 43. Within the placebo
cohort (Table 3), the majority of patients (n = 10) did not
exhibit any meaningful CRP reduction (<20%); however, CRP
was reduced by more than 50% in three patients, but this was
not associated with an ACR20 response.
The serum concentrations of ACZ885 were determined in
each dose group. The maximal concentration rose in a dose-
proportional manner and reached a mean peak exposure of
329 μg/ml in the 10 mg/kg group after the second infusion,
which decreased to less than 10 μg/ml by day 113. The
elimination half-life was similar across all dose levels and aver-
aged 21.5 ± 4.9 days (mean ± standard deviation). Details of
exposure and its relationship to pharmacodynamic activities of
ACZ885 will be reported elsewhere.
Safety and tolerability
During the study five serious adverse events leading to hospi-
talization were identified. Among them, two events in the 10
mg/kg dose group (fracture of the left trochanter major after a
bicycle fall and one case of tracheobronchitis) and one in the
0.3 mg/kg group (potential recurrence of angina pectoris)
were considered not to be related to the study medication.
Two episodes identified in the 1 mg/kg dose group (one case
of erysipelas and one case of pulmonary infection) were con-
sidered to be related to study medication. All patients with
infectious events were treated with antibiotics and recovered
fully within the expected time frame. None of the patients pre-
maturely discontinued treatment because of adverse events.
There were no infusion-related adverse events; in particular,
no anaphylactic or anaphylactoid reactions were reported.
Serum samples were tested for the presence of anti-ACZ885
antibodies at baseline, on days 43 and 71, and at the end of
the study (day 113). No formation of anti-ACZ885 antibodies
was detected at any time point during the study.
The overall adverse event profile was almost the same for
active and placebo treatment. Headache was reported less
frequently with ACZ885 treatment (28.9% versus 46.7% for
placebo), and urinary tract infection was reported frequently
often with ACZ885 (21% versus 6.7% for placebo). Overall,
intravenous administration of ACZ885 up to 10 mg/kg given
twice with 14 days between dosing was found to be well tol-
erated without evidence of immunogenicity.
Discussion
ACZ885, a novel human monoclonal antibody directed
against human IL-1β, was found to be highly active in inhibiting
IL-1β mediated arthritis in a preclinical animal model. The low
ED50 observed in this model of aggressive inflammation is
remarkable, because the injected recombinant cells constitu-
tively secrete human IL-1β without any physiological feedback
control. These results prompted us to study ACZ885 in a
dose-escalating, proof-of-concept study in patients with RA –
the first of its kind in humans. The study's primary objective
was to investigate safety and tolerability; therefore, it was not
powered to investigate efficacy or to draw firm conclusions
regarding superiority or inferiority to treatment with anakinra or
TNF blockers in RA. The small sample size of 38 patients
treated with various doses of ACZ885 and 15 patients on pla-
cebo does not allow any definitive conclusion about safety to
be drawn. Whether an increase in infectious episodes under
ACZ885 represents an early sign of the consequences of
Figure 3
Reduction in disease activity and CRP levels following ACZ885 ther- apy in RA patients Reduction in disease activity and CRP levels following ACZ885 ther-
apy in RA patients. (a) Mean disease activity (Disease Activity Score 
using 28 joint counts [DAS28]) levels over time. Baseline adjusted 
mean and standard error of the mean (SEM) from the repeated meas-
ures analysis are presented for patients treated with ACZ885 10 mg/
kg (n = 20) and placebo (n = 15). P values for comparison of ACZ885 
10 mg/kg versus placebo at each time point are presented. (b) Geo-
metric mean C-reactive protein (CRP) levels over time. Baseline 
adjusted mean and SEM from the repeated measures analysis are pre-
sented after transformation back onto the original scale for patients 
treated with ACZ885 10 mg/kg (n = 20) and placebo (n = 15). P val-
ues for comparison of ACZ885 10 mg/kg versus placebo at each time 
point are presented. Normal range of CRP was 0 to 8.4 mg/l.Arthritis Research & Therapy    Vol 10 No 3    Alten et al.
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blocking IL-1 – similar to observations with anakinra [21] –
needs confirmation, and careful monitoring in upcoming larger
studies is required. Immunogenicity and infusion-associated
events were not observed with two intravenous
administrations.
The study provides evidence of a treatment effect by demon-
strating that 50% of patients achieved an ACR20 response up
to day 43 in the highest tested dose of 10 mg/kg intravenous,
along with a robust reduction in serum CRP. No firm conclu-
sion regarding any dose-response relation can be drawn,
because of the small sample size (n = 6) of the cohorts treated
with 0.3, 1, and 3 mg/kg ACZ885. The onset of action in those
who responded was found to be rapid. The majority of these
responders satisfied the EULAR criteria for moderate or good
response or ACR20 response criteria within 3 weeks. Similar
to experience with other biologics for the treatment of RA
patients, there was a subset of patients who did not respond
to treatment. On the other hand, some patients achieved an
ACR50 or even ACR70 response within a short period of
treatment. This observation reflects the common understand-
ing that RA represents a heterogeneous disease and that,
even by applying strict inclusion criteria, the studied disease in
clinical trials is not homogenous. Therefore, a better under-
standing of the pathophysiology on an individual basis is
required if we are to better predict the response to a certain
treatment and hence avoid treatment failures. Consequently,
there is a need to establish biomarkers that have high predic-
tive value; recent progress has been made for TNF blockers
[22,23].
In the current study, CRP reduction was found to be neces-
sary for achievment of clinical response, as expected, but it
was not sufficient to explain or even predict clinical response,
because CRP reduction was also observed in the absence of
clinical response. Therefore, CRP reduction during treatment
does not serve as a predictive biomarker for clinical responses
at the individual level. Furthermore, levels of serum IL-6, TNF-
α and IL-1Ra levels (as measured by enzyme-linked immuno-
sorbent assay) were within the normal range in these patients
and exhibited no conclusive changes during the course of the
study (data not shown). At baseline, total IL-1β levels in serum
were at or below the detection limit of the assay (about 1 pg/
ml) and showed no difference between responders and non-
responders, indicating that baseline serum levels of these
cytokines are of poor predictive value to identify treatment
responders.
Almost all rheumatologists prefer to administer a TNF blocker
rather than anakinra as a first biologic agent to treat RA
patients, concordant with a recent consensus statement, and
national and international registries [3]. Treatment with recom-
binant IL-1Ra (anakinra) has been shown to be effective in RA
[24], but its efficacy appears to be lower than that of TNF-α
inhibitors [25] and its administration is frequently associated
with injection-related adverse events. Whether anakinra's
lower efficacy is due to an inferior biologic role of IL-1 as com-
pared with TNF-α in the pathogenesis of RA or is simply due
to the fact that anakinra cannot fully neutralize IL-1 is currently
unclear. ACZ885 can completely neutralize IL-1β over a long
period of time; it therefore offers an opportunity to study the
relative biological role of IL-1β in the pathogenesis of RA. Fur-
ther and larger studies will determine the efficacy of ACZ885
in treating signs and symptoms in patients with RA, and they
may allow comparison with the efficacies of other biologic
agents.
Conclusion
ACZ885 was found to inhibit IL-1β mediated joint inflamma-
tion in preclinical models. It was well tolerated in this first
proof-of-concept study in RA patients and was associated
with a significant treatment effect in about 50% of patients.
Further studies are warranted to confirm these initial results, to
establish a safety profile, to identify those patients who will
profit most from blocking IL-1β, and to better understand the
biological role played by IL-1β in the pathogenesis of RA.
Table 3
Relationship between CRP reduction and ACR response following ACZ885 treatment
Group CRP reduction at day 43 versus baseline ACR response at day 43
<20% 20% to <50% 50% or more
10 mg/kg ACZ885 <20% 4 0 0
20 to <50% 0 1 1
50% or more 8 2 2
Placebo <20% 9 1 0
20 – <50% 2 0 0
50% or more 3 0 0
Relationship between C-reactive protein (CRP) reduction and American College of Rheumatology (ACR) response at day 43 for patients in the 10 
mg/kg group and patients receiving placebo. Note that two subjects are excluded from the 10 mg/kg ACZ885 because of missing data.Available online http://arthritis-research.com/content/10/3/R67
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